Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Joan Oloff is Making Fashion More Functional

All too often, our choice of wardrobe comes down to function or fashion. We sacrifice comfort to look good, or we sacrifice taste so that we can be comfortable during long days on the job. Increasingly, however, companies are seeking to create pants, dress shirts and shoes that combine runway aesthetic with around-the-house comfort. In…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

All too often, our choice of wardrobe comes down to function or fashion. We sacrifice comfort to look good, or we sacrifice taste so that we can be comfortable during long days on the job. Increasingly, however, companies are seeking to create pants, dress shirts and shoes that combine runway aesthetic with around-the-house comfort. In a fashion landscape dominated by established brands, it can be difficult for a start-up to stand out. By providing customers with clothing and accessories that look great but can also be worn on the job, new brands are able to break through this barrier.

Few designers exemplify this innovative spirit as much as Joan Oloff. A podiatrist by training, Joan set out to make the first line of orthopedically correct high heels. After seeing the issues that traditional high heels cause in her patients, Joan knew there had to be a way to design beautiful shoes that wouldn’t negatively impact the health of the wearer’s feet down the road.

The challenge was taking elements already common in athletic and walking shoes, like offloading pressure points, incorporating shock-absorption and providing proper support, and finding a way to implement these same features in heels. Over the course of four years, Joan worked with designers and manufacturers, in both Los Angeles and Italy, to make her line of shoes fit her standards. It was difficult. The manufacturers didn’t want to do things her way. But she pushed ahead.

“If I’m not going to be a game-changer, if I’m not going to disrupt the way high heels are made, there’s no point for me to do this,” Joan said in an interview with the San Francisco Chronicle.

Her perseverance paid off and today, Joan Oloff’s shoes have built-in arch support, cushioning material in the ball of the foot and a lower heel pitch, all of which allow the entire foot to comfortably share the body’s weight. Perhaps the most impressive aspect of her line is simply the diversity of options. Made by hand, the latest collection has everything from sandals to knee-high boots. The beauty of the line, combined with the comfort of the shoes, have garnered Joan a loyal following. One surgeon in Santa Fe owns ten pairs of the shoes as they allow her to work without discomfort be it in her office, visiting patients or even conducting an hours-long surgical procedure.

While her customers all praise her shoes, Joan also has proof to back up her claims that she makes healthy heels. Using CurveBeam’s revolutionary pedCAT technology, Joan is able to show weight-bearing CT scans of her shoes in action. When compared side-by-side with the same scans of someone wearing standard heels, it is obvious that Joan’s shoes provide evenly distributed support and stable positioning while other shoes have toe crimping and no arch support, creating a painful experience for the wearer.

Just like Joan Oloff, CurveBeam is dedicated to changing the game. By creating innovative 3D scanning technology that provides a complete view of a patient’s lower extremities, the pedCAT has given podiatrists, physical therapists, and others the ability to give their patients the proper treatment they need. Learn more about pedCAT here.

Read more at curvebeam.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

The FDA approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara for multiple inflammatory diseases, which means it may be substituted without consulting the prescriber, subject to state pharmacy laws. A Springer analysis reported 26 interchangeable biosimilars approved since 2020 and said average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024. The operational pressure shifts to formulary, payer, and specialty pharmacy workflow design.

  • 01Interchangeability is becoming the default ask, not an afterthought: Springer found 17 of 26 approvals pursued interchangeability concurrently, which changes how buyers should time contracting and conversions.
  • 02Springer reported average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024, which can compress planning windows for monitoring and implementation.
  • 03A new interchangeable ustekinumab option means the hard work is no longer clinical, it is operational: NDC mapping, EMR preference lists, substitution rules by state, and patient communications decide whether savings show up.

Sep 8, 2026

AAO-HNSF hearing loss guideline moves audiograms and amplification into primary care

AAO-HNSF’s new age-related hearing loss guideline calls for screening adults starting at age 50 and escalating to otoscopy, audiogram, and appropriately fit amplification. It shifts hearing loss from “patient complaint” to a routine primary-care workflow. The pressure shows up in audiology capacity, referral design, and documentation standards.

  • 01Screening at age 50 becomes a repeatable workflow, so capacity planning shifts from episodic ENT referrals to steady primary-care volume, especially where annual wellness visits are a dominant access point.
  • 02The guideline’s escalation sequence, screen, otoscopy, audiogram, amplification, then cochlear implant candidacy evaluation, creates a measurable funnel that health systems can instrument in the EHR and manage like any other pathway.
  • 03Asymmetric loss remains a separate trigger for MRI in many settings, and 2026 pre-proof work using NHANES and SEER highlights why imaging criteria choices can swing scan volume, a budgeting and radiology access issue, not a clinical footnote.

Sep 7, 2026

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

Accenture will keep supporting Australia’s My Health Record under a new three-year contract. ADHA is moving the platform to a multi-supplier operating model. The shift raises questions about shared integration discipline, tooling, and accountability when changes hit production.

  • 01Multi-supplier delivery is spreading across national-scale health platforms, as ADHA's My Health Record shift shows, moving risk from vendor selection to integration, runbooks, and accountability.
  • 02GenAI model upgrades are arriving with healthcare-specific claims, but the procurement work moves to evidence, safety controls, and monitoring once models sit inside clinical workflows.
  • 03Embedded AI expands the cyber asset inventory problem: if teams cannot discover the AI components across endpoints and devices, they cannot reliably secure or audit them.

Sep 7, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512